-
Post date
June 29, 2022
-
Posted by
Kieran Robertson
-
Posted in
Ecstasy, Health Canada approval, Health Canada restricted drug amendments, Mushrooms, OPTI.C, Optimi, Optimi Health, Optimi Health Corp., psilocybin, psychedelic assisted therapy, psychedelic drug market, Psychedelics, SABI Mind, SAP, Special Access Program
-
Post date
June 29, 2022
-
Posted by
Kieran Robertson
-
Posted in
Ecstasy, Health Canada approval, Health Canada restricted drug amendments, Mushrooms, OPTI.C, Optimi, Optimi Health, Optimi Health Corp., psilocybin, psychedelic assisted therapy, psychedelic drug market, Psychedelics, SABI Mind, SAP, Special Access Program
-
Post date
February 10, 2022
-
Posted by
Kieran Robertson
-
Posted in
2021 psychedelics stocks, 2022 canadian psychedelics stocks, 2022 psychedelics stocks, alcohol use disorder, AUD, best psychedelics companies, best psychedelics stocks, best psychedelics stocks 2021, canadian psychedelics stocks, canadian psychedelics stocks 2021, canadian psychedelics stocks 2022, clinical trial, clinical trials cost psychedelics, clinical trials psychedelics, clinical trials psychedelics stocks, companies doing psychedelics research, EntheoTech, EntheoTech Bioscience Inc., FH.NE, Filament, Filament Health, Filament Health (FH.NE), filament health clinical trials, Filament Health Natural Psychedelic, Filament Health Trials, financial results, Health Canada approval, how to invest in psychedelics, invest in psychedelics, Major depressive disorder, MDD, medical psychedelics, Mushrooms, NEO, Psychedelics, psychedelics market, Psychedelics research, Q3, Q3 2021, SAP, Special Access Program, Today's Idea
